Cited by CrossRef (7)

  1. Mark A. Moyad. Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.). Curr Urol Rep 2023;24:515
    https://doi.org/10.1007/s11934-023-01180-7
  2. Yoo-Bin Seo. Strategies for Long-Term Weight Loss and Maintenance. Korean J Fam Pract 2023;13:128
    https://doi.org/10.21215/kjfp.2023.13.3.128
  3. Jee-Hyun Kang, Kyoung-Kon Kim. Guidelines for obesity clinic consultations in primary healthcare clinics. J Korean Med Assoc 2024;67:240
    https://doi.org/10.5124/jkma.2024.67.4.240
  4. Rieko Kanai, Sachiho Kinoshita, Izumi Kanbe, Mariko Sameda, Shuhei Yamaoka, Osamu Horikawa, Yasuhiro Watanabe, Ichiro Tatsuno, Kohji Shirai, Takashi Oshiro, Atsuhito Saiki. Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes. Obesity Pillars 2024;9:100098
    https://doi.org/10.1016/j.obpill.2023.100098
  5. Vincent Cheng, Kamran Samakar, Adrian B. Dobrowolsky, James D. Nguyen, Stuart A. Abel, Andrea Pakula, Andrew Bernard, Matthew J. Martin. Common postbariatric surgery emergencies for the acute care surgeon: What you need to know. J Trauma Acute Care Surg 2023;95:817
    https://doi.org/10.1097/TA.0000000000004125
  6. Xin‐Hui Pan, Bryan Tan, Yip Han Chin, Ethan Cheng Zhe Lee, Gwyneth Kong, Bryan Chong, Martin Kueh, Chin Meng Khoo, Anurag Mehta, Priyanka Majety, Gowtham R. Grandhi, Georgios K. Dimitriadis, Roger Foo, Nicholas W. S. Chew, Carel W. Le Roux, Mamas A. Mamas, Mark Y. Chan. Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis. Obesity 2024;32:840
    https://doi.org/10.1002/oby.24002
  7. Arya M. Sharma. The Transformative Impact of New Anti-Obesity Medications: A Paradigm Shift in Medical Practice?. Journal of Obesity & Metabolic Syndrome 2023;32:285
    https://doi.org/10.7570/jomes23078